Dr. Dietrich Haubenberger of NINDS/NIH Gives Presentation On ET Outlook

title-page-et2016-presentationWhen we founded HopeNET 5 years ago, we felt that the thing that the ET community needed most at that time was HOPE – hence the name. In the meantime, we have strived hard to bring some hope to all with ET. Accordingly, HopeNET played a key role in having the ET conference at NIH in May 2015. Since that conference, there has been a big increase on the part of industry in developing new treatments for ET. Dr. Dietrich Haubenberger of NIH is probably in the best position to know what is going on with ET. He came to the Falls Church, Virginia ET support group on October 14th and made the attached presentation, Essential Tremor 2016: A look into the pipeline. There has never been a better time than right now for hope – for all of us in the ET community.

— Peter

Dr. Dietrich Haubenberger of NINDS/NIH Gives Presentation On ET Outlook

title-page-et2016-presentationWhen we founded HopeNET 5 years ago, we felt that the thing that the ET community needed most at that time was HOPE – hence the name. In the meantime, we have strived hard to bring some hope to all with ET. Accordingly, HopeNET played a key role in having the ET conference at NIH in May 2015. Since that conference, there has been a big increase on the part of industry in developing new treatments for ET. Dr. Dietrich Haubenberger of NIH is probably in the best position to know what is going on with ET. He came to the Falls Church, Virginia ET support group on October 14th and made the attached presentation, Essential Tremor 2016: A look into the pipeline. There has never been a better time than right now for hope – for all of us in the ET community.

— Peter

Pictures from the 5th International Symposium on Focused Ultrasound

Ferre GrishamReidUnkPeter GrishamPeterReid

August 31, 2016, Bethesda, Maryland – These pictures show HopeNET director Peter Muller a week after his focused ultrasound procedure attending the annual forum on focused ultrasound advances. Seen, from left-to-right, Peter with Maurice Ferré, MD, CEO of INSIGHTEC, the medical device company behind the magnetic resonance-guided focused ultrasound (MRgFUS) technology; and with symposium keynote speakers John Grisham, bestselling author who recently penned The Tumor, a medical fiction story about focused ultrasound, and Chip Reid, CBS reporter and national correspondent who is frequently on CBS This Morning.

Essential Tremor Symposium at Holy Cross Hospital

Shown is Peter Muller beginning the joint Essential Tremor support group meeting at Holy Cross Hospital on June 6, 2015.
Shown is Peter Muller beginning the joint Essential Tremor support group meeting at Holy Cross Hospital on June 6, 2015.*

The June 6th Essential Tremor support group meeting at Holy Cross Hospital in Silver Spring, MD brought together close to 50 members of area Essential Tremor support groups from places like Silver Spring and Columbia, Maryland and Loudoun County and Falls Church, Virginia. There were two speakers preceded by remarks by Peter Muller from HopeNet. Muller informed the audience about what happened last month at a conference HopeNet worked to arrange, held at the National Institute of Neurological Disorders and Stroke (NINDS), a part of NIH. Forty neurologists and ET researchers attended the conference. What they agreed on is that treatment for ET is not possible if they do not know what the condition is. ET presents differently in each person, with varying symptoms such as hand tremors, head tremors, voice tremors, etc., and there can be overlap with other conditions such as Dystonia. These experts decided it would be beneficial to use hand tremors as the focal point to pinpoint what ET is, which suggests there will be upcoming studies.

Moving on, the support group audience was fortunate to hear from Dr. Maguire-Zeiss of Georgetown University’s Department of Neurology who gave a brief overview of the mechanisms in the brain thought to be involved in ET such as the cerebellum, motor cortex and thalamus. There is a question about the role the inferior olive plays as well. Maguire-Zeiss focused on neurons and likened the movement of neurons in the brain to an (electric) circuit and pointed out that if there is a “hiccup in the loop,” that can lead to more body movement (as seen in ET) or less body movement (as seen in Parkinson’s Disease).

Another guest speaker was Dr. T. Sean Vasaitis, Professor of Pharmaceutical Sciences at University of MD, Eastern Shore, who has ET himself and is a practitioner and instructor of the Chen style of Tai Chi. Dr. Vasaitis spoke about body control and elaborated on the benefits of Tai Chi such as reducing stress, releasing tension, improved calm, sleep quality and other cognitive functions. He is exploring the idea of a study on the effects Tai Chi can have on ET patients and speculated that starting out there would be a suggested practice of Tai Chi 2-3 times per week.

HopeNet organized this support group meeting and continues to work toward helping people with ET. Another similar meeting of these support groups is likely to be planned for the fall season, and will again be open to other interested individuals.

Please check www.thehopenet.org for upcoming schedule and registration information.

Lisa Gannon
Silver Spring Support Group Member

* PHOTO BY LISA GANNON

Shaking On Capitol Hill

April 2, 2014 — A handful of members from the Essential Tremor Support Group that meets monthly at Leisure World in Silver Spring made a trip to Capitol Hill to meet with Congressman Chris Van Hollen’s Legislative Assistant for Healthcare, Erika Appel, to discuss concerns over quality of life for people with Essential Tremor, a neurological condition.

E.T. can present with hand tremors, voice tremors, loss of voice, head tremors, and leg tremors. Prudy of Ashburn attended with her sister, Sara, of Derwood, in order to speak for Sara who cannot talk because of the condition. Sara began having a wavering voice years ago and as the condition progressed she lost her voice completely and faces not only social isolation but real danger from not being able to communicate. Another attendee was Thom who came with his wife Mary so she could speak to how it is for a family member supporting the person with E.T. Thom had Deep Brain Stimulation, brain surgery that involves a pacemaker placed below the neck that helps control the electrical signals and calm the tremor. Unfortunately for Thom, the electrical wire placed in the brain is close enough to the speech center to have impaired his speech which is slurred as a result. Charley, another member, lost his job last December when he was asked to take early retirement and suspects that his tremor may be in part to blame since he was an ESOL teacher who taught writing, which is of course quite difficult when your writing is illegible from the tremor. And lastly I attended, a 50 year old woman, and experience like many others the anxiety-like physical and psychological effects of the tremor and its negative impact on work and social life. As the condition progressively gets worse, I fear for my future in terms of unemployment [my excessive shaking at job interviews does not likely help me get the job] and disability [since the tremor is not bad at all times, I certainly would not qualify for disability, but in situations such as job interviews it is truly a disability].

Prudy spoke and gave some perspective on E.T. in the U.S. She recollected statistics from several years ago that approximately 1 million people have Parkinson’s Disease whereas E.T. affects about 10 million. Most in our group think people with the condition do not know they have it and attribute their symptoms to anxiety or nerves. It has been well-established that having an alcoholic drink helps many with this condition, that the octanol in alcohol helps diminish the tremor for a short time, and NIH has conducted research studies to isolate the octanoic acid from alcohol for use in pill form. These studies are years old, and there is frustration among this group that development of pharmaceutical octanoic acid is stalled. While there is the newer focused ultrasound treatment, and Sara mentioned she thought there were 9000 on the waiting list, we lamented over the lack of knowledge among neurologists about our condition, and about the complete lack of development of any drug specifically made to treat E.T. The few medicines that are prescribed were developed decades ago for other conditions like high blood pressure and epilepsy and happened to alleviate the tremor for only some people. It was encouraging that Erika Appel wanted to look into the condition further and wondered why a drug had not been developed if there is a market of so many people who have the condition.

The next thing for HopeNET is the May 7th congressional briefing on E.T. sponsored by Congressman Moran’s office.

Lisa Gannon, Silver Spring Support Group Member

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative: The NIH Perspective

On June 12, 2013, Peter Muller, representing Tremor Action Network, attended the caucus briefing as described below.

On June 12, 2013, the American Brain Coalition organized a Congressional Neuroscience Caucus Briefing that explored the recently-announced Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, an unprecedented public-private partnership to revolutionize our understanding of the human brain. The BRAIN Initiative is poised to capitalize on scientific advancements to provide researchers with new tools to identify ways to treat, prevent and even cure brain disorders. The Capitol Hill event was sponsored by the American Academy of Neurology and the Society for Neuroscience.

Congressman Earl Blumenauer (D-OR), Congressional Neuroscience Caucus co-chair, welcomed nearly 100 attendees to the briefing, a mix of Hill staff and representatives from advocacy organizations. Rep. Blumenauer noted the importance of NIH research and introduced the Briefings speakers Dr. Francis Collins, Director of the National Institutes of Health and Dr. Story Landis, Director of the National Institute for Neurological Disorders and Stroke.

Dr. Collins provided a general overview of BRAIN. He said that NIH is excited about this initiative and they think the time is right – progress in neuroscience is yielding new insights into brain structure and function; progress in optics, genetics, nanotechnology, informatics, etc. is rapidly advancing the design of new tools. Dr. Collins then laid out the FY2014 BRAIN Initiative partners. Government agencies include NIH, DARPA, and NSF; private organizations include the Allen Institute, Howard Hughes Medical Institute, Salk Institute, and The Kavli Foundation. He then provided the goals of the NIH BRAIN Initiative and how it will work. The Plan will be developed by a working group of the Advisory Committee to the NIH Director, and will include timetables, milestones and costs. The NIH BRAIN Working Group will seek broad input and will deliver a final report in June of 2014.

Dr. Landis spoke about the potential of the BRAIN Initiative for understanding and treating brain disorders, and how outcomes from BRAIN might have applications for specific diseases. One such example Dr. Landis provided was deep brain stimulation, and how it is a significant benefit for Parkinson’s patients in the mid-course of the disease. OCD, intractable depression, dystonia, essential tremor and other circuit disorders can be treated with deep brain stimulation by using different electrode placements. Dr. Landis outlined the NIH Blueprint for Neuroscience Research, and how funds allow exploration of new strategies to accelerate progress in the neurosciences. She talked about the Neuroinformatics Framework, which is the largest searchable collation of neuroscience data on the web, the largest catalog of biomedical resources, and the largest ontology for neuroscience. Dr. Landis discussed the Human Connectome Project, the Blueprint Neurotherapeutics Project, and the ‘Virtual Pharma’ Model, as well.

During the Q&A, Dr. Collins addressed the challenges that the tight funding environment and sequestration present to NIH. He noted that BRAIN would likely be funded at a much higher level if more funding were available and that all areas of research suffer given the current situation. One attendee asked how NIH plans to involve the patient advocacy community. Dr. Collins said the NIH is working with the American Brain Coalition in determining the best way to educate and engage the patient advocacy community.

Source:  American Brain Coalition eNEWSLETTER

Presentations

The potential of the BRAIN Initiative for understanding and treating brain disorders
Story Landis, PhD
Director, NINDS
Neuroscience caucus
June 12, 2013

NIH and the BRAIN Initiative
Francis S. Collins, M.D., Ph.D.
Director, National Institutes of Health
Congressional Briefing June 12, 2013

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative: The NIH Perspective

On June 12, 2013, Peter Muller, representing Tremor Action Network, attended the caucus briefing as described below.

On June 12, 2013, the American Brain Coalition organized a Congressional Neuroscience Caucus Briefing that explored the recently-announced Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, an unprecedented public-private partnership to revolutionize our understanding of the human brain. The BRAIN Initiative is poised to capitalize on scientific advancements to provide researchers with new tools to identify ways to treat, prevent and even cure brain disorders. The Capitol Hill event was sponsored by the American Academy of Neurology and the Society for Neuroscience.

Congressman Earl Blumenauer (D-OR), Congressional Neuroscience Caucus co-chair, welcomed nearly 100 attendees to the briefing, a mix of Hill staff and representatives from advocacy organizations. Rep. Blumenauer noted the importance of NIH research and introduced the Briefings speakers Dr. Francis Collins, Director of the National Institutes of Health and Dr. Story Landis, Director of the National Institute for Neurological Disorders and Stroke.

Dr. Collins provided a general overview of BRAIN. He said that NIH is excited about this initiative and they think the time is right – progress in neuroscience is yielding new insights into brain structure and function; progress in optics, genetics, nanotechnology, informatics, etc. is rapidly advancing the design of new tools. Dr. Collins then laid out the FY2014 BRAIN Initiative partners. Government agencies include NIH, DARPA, and NSF; private organizations include the Allen Institute, Howard Hughes Medical Institute, Salk Institute, and The Kavli Foundation. He then provided the goals of the NIH BRAIN Initiative and how it will work. The Plan will be developed by a working group of the Advisory Committee to the NIH Director, and will include timetables, milestones and costs. The NIH BRAIN Working Group will seek broad input and will deliver a final report in June of 2014.

Dr. Landis spoke about the potential of the BRAIN Initiative for understanding and treating brain disorders, and how outcomes from BRAIN might have applications for specific diseases. One such example Dr. Landis provided was deep brain stimulation, and how it is a significant benefit for Parkinson’s patients in the mid-course of the disease. OCD, intractable depression, dystonia, essential tremor and other circuit disorders can be treated with deep brain stimulation by using different electrode placements. Dr. Landis outlined the NIH Blueprint for Neuroscience Research, and how funds allow exploration of new strategies to accelerate progress in the neurosciences. She talked about the Neuroinformatics Framework, which is the largest searchable collation of neuroscience data on the web, the largest catalog of biomedical resources, and the largest ontology for neuroscience. Dr. Landis discussed the Human Connectome Project, the Blueprint Neurotherapeutics Project, and the ‘Virtual Pharma’ Model, as well.

During the Q&A, Dr. Collins addressed the challenges that the tight funding environment and sequestration present to NIH. He noted that BRAIN would likely be funded at a much higher level if more funding were available and that all areas of research suffer given the current situation. One attendee asked how NIH plans to involve the patient advocacy community. Dr. Collins said the NIH is working with the American Brain Coalition in determining the best way to educate and engage the patient advocacy community.

Source:  American Brain Coalition eNEWSLETTER

Presentations

The potential of the BRAIN Initiative for understanding and treating brain disorders
Story Landis, PhD
Director, NINDS
Neuroscience caucus
June 12, 2013

NIH and the BRAIN Initiative
Francis S. Collins, M.D., Ph.D.
Director, National Institutes of Health
Congressional Briefing June 12, 2013

Speaker Dr. Kathy Maguire Zeiss, Assistant Professor Neuroscience, Georgetown University – Silver Spring Support Group Meeting

Essential Tremor Support Group meeting
Silver Spring, MD
May 2, 2013

Guest speaker: Dr. Kathy Maguire Zeiss, Assistant Professor Neuroscience, Georgetown University

Peter Muller, head of HopeNET, opened the meeting announcing that in June there would be a special Saturday meeting, June 8th at 10am at Holy Cross Hospital, bringing together all local area support groups from this Silver Spring group, the Falls Church VA, and Columbia MD groups, plus the St. Louis support group will teleconference in. Kathleen Welker, the head of Tremor Action Network, will be attending from California,

In introducing our guest speaker, Dr. Maguire-Zeiss, Peter mentioned he recently heard her speak to the Falls Church support group. Being a part of the American Brain Coalition, he thinks having a wider perspective of what’s going on in neuroscience will lead to better treatments for Essential Tremor (ET).

Dr. Maguire-Zeiss mentioned that a large part of the attention in neuroscience goes to Alzheimer’s disease and filled us in on her background that includes working mostly on Alzheimer’s and Parkinson’s disease. What she’s studied she believes is applicable to other diseases where neurons are dying. Her undergraduate degree in biochemistry was followed by graduate school and a PhD at Penn State University. Her postdoctoral training was at the University of Pennsylvania. Her late husband passed away from a brain tumor – in her career she works to study the brain.

She explained the basics to us, that the brain has 4 main cell types that do things involving intention to move, moving, controlling movement, thoughts, and consciousness. The main cell types are split into two groups: glia and neurons. Glia can be broken down into 3 types of cells: microglia, astrocytes, and dendrocytes. The word ‘glia’ in Greek means glue so for the longest time people thought it did what glue does, keeping things in place. We now know each of these cells has a special function and that your brain would not work without them.

Dr. Maguire-Zeiss went on to describe processes of the brain as it relates to movement disorders like ET and her remarks are very much paraphrased as she presented them:

We’re very inventive as scientists, so microglia are the smallest ones, astrocytes look like stars, and these oliodendrocytes make a special protective coating around your neurons to help them function. Neurons are really important because they carry the info you need. They receive process and send information, therefore having a big function. There are a lot of different types of neurons. I like to think of a neuron like a tree in the spring before all the leaves form. You have these main branches and then off of these branches you have the smaller ones. Then you have one large straight branch. This part that looks like a tree without branches (drawing) is where the cell receives its information (dendrites). This is where you process and send information. So we have special names for these.

There’s a tree that has these little protrusions everywhere that later make blossoms, and remarkably dendrites have these little protrusions too and they’re called spines. So there is lots of this everywhere. The spines are areas where other neurons talk to these neurons. This is what you call a cell body. It takes this information and says it has to do something with this, like make a protein or something, and then it sends the information down here to what is called an axon. Each neuron has one axon and that axon goes to wherever it’s supposed to go. So for instance in your brain if you want to move your arm, one neuron will receive information from another part of the brain that says, I want to move my arm, and then it sends that info through these to the cell body. Then this guy sends the message to my spinal cord where it controls my arm. These long axons are really important – the info has to be sent a really long way so they need a lot of energy (just like if you would if you went for a longer run verses a shorter run) which comes from up here (the brain). If this guy’s not healthy you don’t have enough energy for this. So these guys end up coming into this area (they look like little buttons so we call them buttons). Those little buttons come over here and there’s another cell here. The cool thing about the brain is we have between 10 to100 billions of these neurons in our brain. You add these to it, we call them synapses, and we have trillions of these connections in your brain. So these guys (microglia) are all around here doing different things: microglia is like white blood cells that attack a foreign object. There’s a tight barrier called the blood brain barrier wrapped around the brain and you guys probably know that some of the drugs you take will cross or won’t cross that barrier. That’s really important because if you didn’t have that barrier and had a cold. Then all that bacteria would go in your head too and that’s really bad because it’s in this closed space. Because the white blood cells don’t get in there, they’re job is to take care of things that sneak in there. Also, cells die and get damaged: those guys (microglia) are like little pac-men, they chew up and eat debris as they’re moving all the time in your brain. There’s a really cool YouTube video where you can see them moving around. We call that, they “survey”. That’s their main job. What we find is in diseases they do it too much. These guys, the astrocytes, they help support this whole system. The way these guys normally talk to each other (the axon and the spine that’s on the dendrite) is this guy has chemicals that he releases. Then the spine has little receptors for that chemical, specific ones that only bind that chemical – that’s how they talk. But they dump it out into this area, synaptic cleft, dumping those neurotransmitters there. So these cells (glia) take up these neurotransmitters. These guys help to make this work better, they encapsulate it with a protein and lipid combination called myelin, and they insulate this axon. When you insulate something like an electric wire, you can send the electricity signal much faster. And that is what our bodies have done. If they didn’t do this you’d have to have a very big axon to carry all that information. If you’ve ever seen a giant squid – they’re invertebrates without bones and they make these giant, very big axons, thicker than a pencil. If you had to have a hundred billion pencils in your head, how big would your head have to be? So we’ve evolved to have this insulator. So now we know what they look like and how they talk to each other. Then the idea is how they work in your brain. If I took a picture of a brain it looks like this (cross section drawn). If you’re talking about moving since that’s what I’m interested in in the lab, there’s a part of your brain called the motor cortex that helps you with moving. If you map out the motor cortex, there are spaces in here for your feet, knees, arms, trunk, hands (a really big space), and there are spaces for your tongue and your eyes. The ones that have more movement and really precise movement have a larger part of your cortex – for example, your fingers because it takes a lot of effort to move. This is called a homunculus. How do we know that these areas are involved? We’ve done research. If you have a person who’s had a stroke (for every person a stroke is different), it depends on where the stroke occurred and where the blood supply was limited and what died. So if you had a stroke in an area that controls your arms on one side of your brain, then you’ll have someone who has a hard time moving their arm. They will subsequently have to keep practicing and doing things over and over again. So they’ll recover a little bit but probably not completely. This is how we have learned how the brain works. If you want to move your arm, you would have to have info from this area of the brain and it has to get down here to the area of the spinal column that controls the arm. It doesn’t really get interrupted by anything – it is one synapse and one set of neurons that control your crude movement. It’s good in the sense that it’s fast and it’s bad because there’s nothing helping it along the way. If you damage it up here you really have a lot of damage. But remember we have to have information from the outside coming in. For example, to tell you that’s an uncomfortable way you have your legs crossed – so I want to move. We call this sensory information and it comes in a different way but ends up right around the same place and talks back to it to help control it.

So what happens in Parkinson’s or Essential Tremor is all that circuitry going down is functioning okay but what’s not functioning very well is the area in between. So let’s look at the brain this way (drawing). This is the cerebellum. And this is your frontal cortex which controls you from doing dumb stuff .This area is in the middle of the brain acting like a black box and we call it part of the midbrain structures. So what happens in these areas if there’s damage – it’s not like you can’t move it’s just that you’re not moving the way you want to. You either have a tremor at rest, an intention tremor, or one that’s there all the time but worse under those two circumstances. And there are two areas of the brain that control fine movement, for example, if you want to pick up a cup of coffee and bring it to your lips. You guys are all aware of that I’m sure. One area is called the basal ganglia. So if we look at it as an engineer, this is the motor cortex. In order to move it needs another area of the cortex to say, I want to move. It doesn’t just spontaneously move. It needs information. So in this circuit that information comes down to another area deep in the brain here that we give another name to, the striatum. This area has two pathways with both of them ending up in the same place. We call them direct and indirect pathways. They help us to balance what to do and help control the movement. All that information goes into another place involved in Parkinson’s and ET, called the thalamus. That’s your relay center so that’s the area that sends your information back up here to say this is how I want to make the movement – I want it to be a smooth movement, or I want it to be a jerky movement, however I want to have it. And when it doesn’t work that’s when you have movement problems. In Parkinson’s there’s this area of the brain that has a neurotransmitter called dopamine and it controls this. In Parkinson’s those neurons die and because of that Parkinson’s patients aren’t getting the right information to this part of the cortex so they can’t start moving. If you want them to walk and they just hesitate, you have to distract them somehow. There is a trick we can use for the brain to get them to go. If you clap in rhythm they walk in the rhythm of the clap to get started. Another problem these patients face is tremor at rest. Clinical doctors will rate tremors different ways by how fast the tremor is. Most of the Parkinson’s patients who first go to the clinic have already lost a lot of their neurons; about 80% of their neurons have died. The plus is that it’s remarkable they have a little tremor and still have a lot more neurons there than they really need to have normal function. So if we could just diagnose them a little earlier then a lot of the treatments that we know work really well to save those neurons are going to make all the difference in the world for them. So we have lots and lots of people at Georgetown and all over the country looking for what they call biomarkers, ways to know if you have the disease before you have that first symptom. In Parkinson’s we’re getting clues about the rest of the body. What clinicians do is create histories of these patients and what’s come to the surface is that a lot of Parkinson’s patients have REM behavioral sleep disorder way before they have the disease. Normally when you or I are asleep we are paralyzed. We have dreams but we don’t do anything about them. With REM Behavioral Sleep Disorder, you don’t’ have this shutoff so if you’re having a fight in your dream, you’ll punch the person next to you. I guess they just push each other and say, “Hey you’re having a dream”. What they found is that this happens 5-6 years before the tremor. Another thing Parkinson’s patients get way beforehand is constipated. Now you can imagine saying to your physician I’m constipated and him saying, “Oh you have Parkinson’s”. No, he has a list of other things before that. So several groups are looking closer at histories and, are checking people who’ve had a colonoscopy. Looking at biopsies of pre-Parkinson’s patients they have some pathology. There is a certain protein that’s also in the patient’s neurons. So now we’re getting this idea that it’s not just happening in the brain, it’s starting in the gut. We have other types of minor changes when put together look like they have Parkinson’s before they have the disease. That’s really important because it gets at how we can treat these patients with peptides and proteins that can save those neurons. The problem is when we take it to a clinical trial they’ll only allow us to do the trial on patients who have had every other type of treatment. By then there are no neurons for us to save. So we have to change the whole culture about how we do things. That’s one big hurdle I’m sure is the same in every disease we’re trying to study.

In my lab studies, in this whole process I’m asking, what are those glia cells doing. They have to be important in this. What we discovered is that in these areas where neurons are dying, the glia cells are very active and they’re dumping things out into the environment that are killing neurons. So we’re trying to understand that particular pathway and how they get activated. It looks like they get activated by the bad protein that was in the gut that’s also in the neurons. When they release the protein they create bad cells – so we’re trying to block that. So you may have seen news about clinical trials for Alzheimer’s, Parkinson’s, Huntington and ALS where they give them anti-inflammatory drugs that didn’t work very well. It worked well with mice in the lab but not with people. One reason we think is because we’re not getting the right pathway. So we’re trying to narrow that pathway. Another reason is it may not be good to block all your ability to have inflammation because if you have another infection that would be a problem. In Parkinson’s that’s what we think is happening.

In ET, the cerebellum sends info to the thalamus which sends info back to the motor cortex. It’s in this area I think that they believe is where the biggest problem occurs in ET. And there are a couple different types of neurons in this area that are being studied. They are cerebellar neurons: one’s called dentate (they look like teeth) and they send information to another area called Purkinje cells. It’s the cross talk in there that they think is messed up. That’s why some of you may be on a replacement for the neurotransmitter GABA, because that’s the neurotransmitter that talks to these two. Again, if there’s an interruption here, then if you get to the motor cortex you can no longer have normal movement. The job of this guy (GABA) is to prevent a lot of movement. Without it there to dampen it, you don’t have any control of your thalamus so it wants to move all the time. It’s the loss of really good control that gives you the tremors. Another disease you may have heard of is Huntington’s disease – they are moving all the time and it’s dramatic. Once you’ve lost control of this major relay center then you’ve lost all your fine movement.

So how do we study this better? We’re good at a couple of things: looking at a specific neuron under a microscope, or growing them in mice. We can even put an electrical probe in them and understand how they talk to each other. So we’re good at one cell measurement. Another thing is we’re able to do pretty well are functional MRIs – where you’re in a scanner and we ask you to do something or show you something. We can see what areas of the brain light up when you’re doing or thinking of a specific task. In fact that’s how they figured out that in the motor cortex there’s info needed before you make a movement. They had patients in the MRI do a specific routine of finger movement and two areas of the brain lit up when thinking about the task and doing the task. Then they had them just think about the task. So what does it mean when it lights up in the MRI? When we’re trying to figure out what area of the brain does something it’s usually some kind of compound that gets converted to glucose – because your brain needs a lot of energy. Your brain is pretty small compared to the rest of your body but it uses 20% of the energy of the body, it uses a lot of glucose. What we’re not good at is understanding what that means. If you had an MRI and you had a memory test one area might light up. There’s this guy named Brodmann and he mapped the whole brain. There are 42 Brodmann areas and each one is related to some task. Your temporal lobe is the area for memory. If it lights up, it tells us some neurons there are important. But we don’t know what’s in the whole group of neurons. The only way to know is to look at postmortem tissue and use all these different techniques and it would take a really long time. So that’s where the Obama Brain Initiative comes in, they decided we need to understand how all these areas of the brain are talking to each other. They want to map the brain. What they plan to do is understand the connections. We’ll start with animal models. One example of what they’ve done so far is a technique called Clarity. You take a mouse brain and it looks very pink and you can’t see through it. There’s lots of tissue as the brain is made up of cells and a lot of fat. They took the mouse’s brain and put it through a couple of chemical baths. Afterwards you could see through it. They got rid of all the fat and you could see all the cells still in suspension in the brain. It’s the most amazing thing. What’s the beauty of that? Well we have a lot of techniques that will allow us to look at certain sets of neurons because we can make certain neurons different colors. Plus we can see where they go in 3 dimensions. So this is an example of the power that can come out of this Brain Initiative. Another technique developed by this researcher involved using two different mice. When mated he got a mouse whose neurons in one specific area were a certain color. He could knock out genes or stop them from being expressed. So this is very powerful. So this initiative should hopefully make a big difference. Even when you have critics saying you’ll only get a little information, I’d say it’s better to get a little information than none.

A question was posed as to whether there are indicators for ET that are similar to the ones found in the gut for Parkinson’s. Dr. Maguire-Zeiss said she doesn’t think so but wants to show us something about that process and why that’s important. In PD they have a protein called alpha-syncline which has been linked to familial disease. So there are a small group of patients that have a mutation in this gene, and they go on to have Parkinson’s. So once we knew this protein was involved, the field exploded and people did everything they could with this protein. This protein is small and it doesn’t have any structure to give it its function. This is very unusual. We made knockout mice that never had it. As not losing this protein did anything, it must have been a gain of toxic function. So then people started investigating how that can be. And what we noticed was in PD the neurons under a microscope had these things that looked like perfect circles in these neurons. They named it after the person who found it, a Lewy body (see black circle in picture of cell with nucleus).

When they found out about this mutation, they wondered if the alpha-syncline protein was in the lewy body and sure enough it was. So labs have been studying the protein lewy body. It aggregates into a very large protein, and when that happens the cell starts to die. This happens in the peripheral nervous system that innervates the gut in a subset of Parkinson’s patients. So there are a group of patients with PD that have this lewy body pathology but I don’t think everyone does. I’ll give you my opinion but it’s not Georgetown’s opinion. What we’re finding in the PD patients: they aren’t all the same. They might have more of a tremor in their hands but less problems initiating movement, or they could have a less severe tremor but have more memory problems. It’s wrong to group people together because then the therapies will become the same, and they can’t be because you’re going to have different types of tremors. I think you’re going to have the same thing with ET. People have tremors in different areas and are more or less responsive to different drugs. I recommend that you advocate with your physician to see if you fit in this bin with everyone else or is there something extra that needs to be done.

We have found that we have this huge amount of microglia and then we get inflammation. We know this from imaging studies of Parkinson’s patients. There’s a specific thing you can put in the blood that microglia will bind to. What they see in Parkinson’s patients is when there is death of neurons in one specific area the whole brain starts to light up, and there’s inflammation. The same thing happens in Alzheimer’s disease. So that’s why we think this is an important link between many diseases. What we found is one particular structure that activates. Normally this small protein is found in the cells, that does not activate the microglia. So this structure has to be this one. We hope that as we get more data and work with other labs that are working to develop compounds to block the inflammation that it’ll be, not a cure, but an adjunct therapy to whatever patients are already having. We want to keep the immune response down because it’s really damaging other cells in the area.

Peter Muller said there are two areas you can donate your brain: Columbia University and University of Arizona. They’re taking different approaches. What’s been interesting is that Columbia has found lewy bodies in ET and Arizona has not. It may be because Columbia is getting older brains. Dr. Maguire-Zeiss said studies have been done on microglia in mice. If we find something interesting, we go to human tissue. You have to wait before using human tissue until you are almost 100% sure. It’s so hard to get human tissue. Georgetown gets brains from Columbia & Harvard. The problem is not so much the diseased brains but control brains.

Clinical neurologists have a lot of pressures such as insurance issues and pressures to see a certain number of patients. If they don’t, they won’t have a job for long. So this is a problem. And I think the brain initiative will only probably occur at a few unique places to start with – where they get support from both the hospital that they work in and a closely aligned university. What comes to mind is a program we’re starting, not that we’re the only ones. We have PhD students mostly in our program. I’m in the program called the Interdisciplinary Program for Neuroscience at Georgetown University. We like it because neuroscience is interdisciplinary. So we have biochemists, cell biologists, pharmacologists and neuroscientists and we all work together and it’s great. What we’ve designed at Georgetown is a track where you get a translational medicine certificate because we can’t really do a degree in it yet. So you do your PhD for instance in our department, neuroscience. Normally you would take a bunch of didactic courses, which are the core of neuroscience. You still do that. In your second year, where students would take electives they are really interested in, they do translational med – courses on how to do clinical research and design clinical experiments. Then when they get to their thesis normally they come to my lab and have a mentor who’s a clinician interested in bridging the clinical basic research. The research that we do is patient-based research with my (neuroscientist) basic science input. We’re trying this new program because we’re seeing that we we’re missing the gap. We’re getting a lot of basic scientists, a lot of clinicians, and very few MD, PhD’s because it’s a hard road and a lot of times the PhD work goes back to the very basic so they don’t get to translate. This is supposed to start next year. We’re pretty excited about it. You can do it in anything so if you’re a cancer biology PhD you can still do the translational stuff. In that case, your mentor would be someone in the Lombardi Cancer Center. The environment is hard for scientists because we have to get our own money to do our work. This new generation doesn’t want to face that. They don’t want to work 60 hour weeks for not a lot of money so it’s hard to get them excited. They’re excited in high school but they get burnt out somewhere along the way.

Related Article: See-through brains clarify connections – Technique to make tissue transparent offers three-dimensional view of neural networks.

 

 

 

Essential Tremor Clinical Research Hope for the Future Conference

Oct 20, 2012 – Fort Belvoir, VA.  As the conference title suggests, this gathering was intended to give hope to those with essential tremor (ET), a condition estimated to affect a high number of Americans, approximately 10 million according to recent literature. There are likely many more who do not know they have it perhaps attributing their shaking hands to being nervous. They may attempt to control it and hide it, rather than seek treatment from a neurologist or more specifically a movement disorder specialist.

There were sixty-two in attendance mostly from area ET support groups in Silver Spring and Columbia, MD and Falls Church and Landsdowne, Virginia. The conference speakers were Dr. Codrin Lungu (Deputy Clinical Dir of Clinical Research), who runs the Parkinson’s Clinic and the medical side of the Deep Brain Stimulation (DBS) program at the National Institute of Neurological Disorders & Stroke; Dr. Claudia Testa (Associate Director Clinical Care and Research, Virginia Commonwealth University, Parkinson’s & Movement Disorders Center); and Dr. Mark Hallett (Chief, Motor Control Section, NINDS).

Peter Muller, Executive Director of HopeNET, a foundation working to increase awareness of ET, gave the opening remarks and let us know the latest about a fairly new procedure called MRI Focused Ultrasound. The University of Virginia did a pilot trial in 2011 whereby mri focused ultrasound surgery was performed on fifteen patients and it must have been seen as a success as evidenced by the 6000 on the waiting list for the procedure. Muller expressed excitement for this technology and introduced Jessica Foley, Scientific Director of the Focused Ultrasound Society. He also introduced Deb Zeller, the President of the Virginia School Nurses Association. HopeNET is jointly working with Ms Zeller on a project to develop a Careplan for use by school nurses with children who have ET.

Muller has been instrumental in bringing people with the condition closer to the medical community in a search for treatment, therapies and ultimately a cure, first in his position as a Community Ambassador to the International Essential Tremor Foundation and now for HopeNET. Muller told the group about the series of surveys being conducted by HopeNET and Tremor Action Network to answer questions on the various symptoms and treatments for ET. The last survey in French was sent to 1400 in France, Belgium and Quebec, Canada.

The first speaker, Dr. Lungu, explained in detail the procedure deep brain stimulation (DBS), a surgical option for those with significant tremor that does not respond to medication. DBS was first performed on an ET patient but now is more often used for another more well-known movement disorder, Parkinson’s Disease. DBS is “electrical therapy” for tremor and is like a pacemaker for the brain that intervenes and normalizes the electrical signals thrown off by disease, as Lungu explained it. DBS is brain surgery that involves drilling two holes in the skull the size of a dime and running electrodes to the deep structures of the brain to block the abnormal signals at the thalamus. The wires run from the thalamus (at a point called the vim) down under the skin behind the ear, down the neck and meets a small battery pacemaker in front of the chest from which the voltage and frequency are chosen. Dr. Lungu made it clear that this surgery ‘is the process, not the event,’ as he said one of his colleagues puts it. The event is the 24/7 adjustment of the electrical stimulation from the pacemaker. There are exclusion criteria for DBS – generally healthy candidates should elect this surgery and those without depression because DBS could make it worse. People also need to know what to expect. For example, the problem is still there after DBS, it is just being covered up symptomatically. DBS has its imperfections such as the fact that the motor part of the brain is separated into left brain and right brain meaning that DBS has to be done one side at a time. The dominant side is often the side done. If a person elects to have both sides done Dr. Lungu prefers to do both sides at once rather than one side now and the other side at a later surgery. He went over the risks of the surgery and the side effects, such as very mild verbal fluency issues, and subtle balance issues.

One attendee suggested getting ET listed in items asked about in the National Health Interview Survey that the Nat’l Center for Health Statistics conducts or the Health & Nutrition Examination Survey.

Dr. Testa spoke about clinical research using genetic research to give people a better understanding of the process. Clinical research as a term means working with people to study human disease. There are clinical trials in which a new intervention is tested in people, observational trials where researchers don’t try to intervene but observe only, and then there are trials dealing with parts of people, such as blood and saliva samples to get DNA for those studies. Where do research questions come from? The researchers think about basic biology of the brain and come up with ideas, and there’s community-based research, such as the surveys HopeNET has been conducting. A VCU neuropsychologist is presently doing a needs-based survey for movement disorders that will help determine ideas on ways to proceed. ET affected individuals are encouraged to participate. Understanding disease in people means looking at the mechanisms of how things work, and then the treatments that need to be developed.

An example of traditional research, called epidemiology, studies large groups of people. A famous one is the Framingham, Mass study consisting of the entire town’s population and has been studied for forty years. The resulting information has been used to find risk factors for heart disease and others. There have also been door-to-door surveys for ET (an epidemiologist and neurologist together that examined people on the spot) in places like Turkey and Spain. In those communities four percent of those over 40 years of age were found to have ET. Another example of working with people deals with looking at the brain to understand the mechanisms involved such as imaging, MRIs or functional scans looking at blood flow. Also the brain banks at Columbia University in NY and at the Arizona Study of Aging and Neurodegenerative Disorders, study the brains donated by people with ET. Research papers from these studies have only been coming out in the past few years. VCU, where Testa works, houses the MidAtlantic Twin Registry, “an amazing resource,” she says in her genetic studies and how they play a role in ET.

Testa explained, “We don’t know of a single gene mutation that causes ET.” A lot of research has been done on the connection between a change in the gene and disease. She spoke about establishing linkages across families using DNA. She explained how the Lingo-1 gene discovered to play a role in ET, does not make protein which implies it doesn’t code (for protein) so there is more work to do to discover details about that interon area – without proteins it is more difficult to study. Testa explained the genome and the detailed clues it might hold.

Our next speaker was Dr. Mark Hallett started his talk by emphasizing people’s participation in research studies since there haven’t been many good animal models. He said trying to address the basic pathophysiology or cause of ET is necessary if a rational treatment is to be created.  We still don’t understand where ET comes from so genetics is an important area to study. Hallett is of the opinion that ET is not a single entity but multiple different entities, meaning a family of diseases, which may be why it’s been difficult to find a single gene that is underlying it.  Hallett explained there may be different types of ET, meaning different pathophysiologies and different therapies. In other words, ET may look the same in two different people on the outside but be different on the inside. When it comes to ET responsiveness to alcoholic beverages, some people respond with a reduction of tremor and others do not – which may be an indicator of ET subtypes. Hallett asked for a show of hands about people’s responsiveness to alcoholic drinks, in that they show an improvement in tremor when drinking alcohol. The majority of the audience raised their hands. Alcohol also can have a rebound effect, he said, whereby once it wears off the tremor returns worse, temporarily.

The Movement Disorder Society is the international society of mostly neurologists, and it has taskforces looking into different types of tremor. Hallett is on a taskforce to come up with better definitions of ET and differentiate its subtypes. Hallett went over the few drugs on the market that help ET. Primidone and beta blockers are the two most common. Sometimes they work for a while and wear off. Some anticonvulsant medicines have benefit: gabapentin, topiramate and others. He said that there is not much work going on in the active development of other drugs for ET. Before he came to the conference today he checked the clinicaltrials.gov website to see what clinical research is being done in the world, and at the moment there are zero – as in no clinical trials being done in the area of ET research. The pipeline needs to be stimulated in this regard.

He gave us the alcohol or octanol story to give a sense of what the process of drug development is like at the NIH. He cited Rodolfo Llinas, a neuroscientist who studied longer chain alcohols and patented them all – saying they would be good for treating any tremor. Octanol worked better in the animal studies than ethanol did. Octanol (an 8 carbon atom) was found to be one of the best longer chain alcohols for the condition and through studies at the NIH they realized that the octanol is metabolized or broken down in the blood  into octanoic acid. How many carbons is best is the question. These studies on octanol and octanoic acid at NIH have taken about 10 years to complete. NIH received a “use patent” to support development. With a pharmaceutical company, NIH started the clinical trial process. Hallett went on to explain that the cost to do an animal toxicology test and to safely try it in humans runs approximately one million dollars. It is difficult to develop a pharmaceutical. The conclusions show that octanol was efficacious to a certain extent, without people getting drunk. At a minimum, it will take several more years for the FDA to approve octanoic acid as a drug. Octanoic acid is a component of the ketogenic diet, a special diet mostly consisting of fat given to children with very severe epilepsy. Someone discovered this diet could help and it’s been used for years. A challenge is how to administer it. It tastes terrible so time needs to be spent encapsulating it. One attendee mentioned to Dr. Hallett that long periods of fasting has helped improve his tremor. Hallett explained that when you fast, your body’s metabolism changes more toward energy from ketones than from sugars. You are converting your body metabolism to a state similar to someone on a ketogenic diet.

Hallett suggested that the alcohol interfering with the calcium channel story may not be right for explaining ET and that maybe a GABA abnormality is a better model for ET than the harmaline animal study model. Another clinical trial from France involves transcranial magnetic stimulation (TMS), external stimulation over the cerebellum that reduced the severity of tremor for a period of time. TMS was given daily for 5 days and the efficacy was for 3 months. TMS has been approved for one type of depression, refractory depression.

Questions were asked of the 3 doctors at the end of the conference. Hallett talked about how relaxation and reducing anxiety and stress help to improve tremor. The hormone, cortisol, in the body is released in response to anxiety and stress and causes the brain to shrink! Dr. Testa talked about observations of the community – the changes in anxiety for people with ET as compared with those without it. There’s a powerful pathway between the unconscious mind and mood states as well as really strong symptoms in the body. Dr. Testa suggested that maybe ET patients experience more anxiety symptoms as a result of the ET. Dr. Lungu concurred that it’s unclear whether the anxiety is part of the biological condition of the disease. Dr. Hallett was asked if there is a connection between epilepsy and ET. He responded that the pathophysiology of epilepsy is well-known. Nothing at any level, at the cellular level, at the thalamus, through EEG or neuroimaging shows a connection. In answer to the question why do the anticonvulsants like primidone, gabapentin and others work for ET, Dr Hallett said these drugs all have multiple effects but we do not know how. Dr. Hallett believes that since the prevalence of ET is high, he thinks pharmaceutical companies should be more interested in developing drugs for it. Dr. Testa said the epidemiology studies indicate age of onset is in general in older adults. Hallett said that patients can help by going to their congressman to say ET is an important concern, and there are a lot of us with the condition.  Joan Marie Barringer, the Support Group Leader from Vero Beach, Florida brought up the DSM Diagnostic Statistic Manual that says many of those with tremor have social phobia.

Conference attendees were pleased with the cooperation of the local medical community at places like NIH and VCU in communicating their expertise, thoughts and findings to the ET community.

Lisa Gannon
Silver Spring Support Group

Ultrasound Clinical Trials at UVA

I feel like I was one of the lucky ones to be included in the focus ultrasound clinical trials at the University of Virginia. This experimental procedure was done at no cost to me through a federal grant. My sister read about the trials in the Richmond newspaper. When I first inquired about the program the possibility of acceptance was bleak. Hundreds of people were interested and I was pretty far down on the list. However most of these could not meet the designated criteria. Prior to being accepted I had to undergo 3 days of testing over a 3 month period. The tests and interviews were administered by a variety of doctors. I met with the UVA coordinator, the surgeon who would perform the procedure ( Dr. Elias ), a neurologist, a physical therapist, a psychiatrist, and a psychologist. I had to have ekgs, bloodwork, and a catscan of the brain.

On 9/7/11 I reported for surgery. My head was shaved and rubber tubing was placed on my head. The operating room was filled with doctors as well as the engineers who built the ultrasound machine. I was placed in a catscan for about 7 hours. It was a long process for me since it took a long time to line up the scanner before they zapped my brain. I was zapped more times than I can remember.

I had 3 follow up visits to Charlottesville to be checked out by the team. They were genuinely interested in how I was recovering. They were very professional and very caring. What a great group.

Prior to the procedure I was told that it would only improve my right hand and it was successful. I can now write in a checkbook and eat in public. I was hoping it would take away some of my head tremors but it didn’t. Head tremors are most common in women.

I have had tremors in my hands since I was in my 20s and they started in my neck/head in my 40s. Even though my right hand is normal, I still have tremors in my head and left hand and my voice is shaky. If I get nervous or do anything out of the ordinary my tremors increase significantly. ET destroys your confidence and it hard to find jobs. You are also aware of people staring at you in public.

I am extremely thankful to Dr. Elias and all of the others that made this a success. This gives encouragement to those with ET. I hope that this process can be used to treat/cure other conditions in the future.

Becky Epton
Member, Falls Church Support Group